Available Technology

Virus Replicon Particles as Rift Valley Fever Vaccines

Rift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed a RVF virus replicon particle (VRP) vaccine candidate. Research findings revealed that immunization of mice with a single dose of the RVF-VRP was found to be safe and elicited immune response that offered 100% protection following exposure to lethal dose of virulent virus. RVF-VRPs have the potential to become effective and efficient RVF vaccines in livestock animals and humans.
Patent Abstract: 
Rift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed a RVF virus replicon particle (VRP) vaccine candidate. Research findings revealed that immunization of mice with a single dose of the RVF-VRP was found to be safe and elicited immune response that offered 100% protection following exposure to lethal dose of virulent virus. RVF-VRPs have the potential to become effective and efficient RVF vaccines in livestock animals and humans.
Benefits 
Murine survival study showed single-dose immunization completely protected mice against a virulent RVFV challenge at 100,000-fold greater than the 50% lethal dose (LD(50)) -Rapid onset of a systematic antiviral response suggests conference of early protection -Low genetic diversity for RVF virus indicates a strong potential for broad-use effectiveness with this vaccine
applications 
Inventors: 

Cesar Albarino

Brian Bird (CDC)

Brian Bird(CDC)➽ more inventions...

Cesar Albarino

Patent Number: 
61/661,614
Internal Laboratory Ref #: 
E-272-2013/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin